Charles Homcy, M.D., partner at Third Rock Ventures, focuses on the formation of companies discovering and developing novel therapeutic approaches. He has significant experience building and leading successful biotech companies and has played an integral role in the launching and building of several portfolio companies, including Global Blood Therapeutics, MyoKardia, TOPICA Pharmaceuticals and CytomX.
Prior to Third Rock, Dr. Homcy co-founded Portola Pharmaceuticals and served as President and Chief Executive Officer. Earlier, he served as President of Research and Development at Millennium, following Millennium’s acquisition of COR Therapeutics in 2002. Dr. Homcy joined COR in 1995 as Executive Vice President of Research and Development and served as a Director of the company from 1998 to 2002. He has been a Clinical Professor of Medicine at the UCSF Medical School and Attending Physician at the San Francisco VA Hospital since 1997. Dr. Homcy was previously President of the Medical Research Division of American Cyanamid-Lederle Laboratories, a division of Wyeth. Dr. Homcy is a Board member of Portola.
Dr. Homcy holds an A.B. and M.D. from Johns Hopkins University, where he presently serves on the board of trustees.